AAAAAA

   
Results: 1-8 |
Results: 8
Liposomal daunorubicin in the treatment of relapsed or refractory non-Hodgkin's lymphoma
Authors: Tulpule, A Rarick, MU Kolitz, J Bernstein, J Myers, A Buchanan, LA Espina, BM Traynor, A Letzer, J Justice, GR McDonald, D Roberts, L Boswell, W Nathwani, B Levine, AM
Citation: A. Tulpule et al., Liposomal daunorubicin in the treatment of relapsed or refractory non-Hodgkin's lymphoma, ANN ONCOL, 12(4), 2001, pp. 457-462
Phase I and pharmacokinetic study of LY309887: a specific inhibitor of purine biosynthesis
Authors: Budman, DR Johnson, R Barile, B Bowsher, RR Vinciguerra, V Allen, SL Kolitz, J Ernest, CS Kreis, W Zervos, P Walling, J
Citation: Dr. Budman et al., Phase I and pharmacokinetic study of LY309887: a specific inhibitor of purine biosynthesis, CANC CHEMOT, 47(6), 2001, pp. 525-531
Treatment of aggressive non-Hodgkin's lymphoma in elderly patients with thiotepa, novantrone (mitoxantrone), vincristine, prednisone (TNOP)
Authors: Lichtman, SM Kolitz, J Budman, DR Schulman, P Vinciguerra, V Hoffman, M Mittelman, A Allen, SL Fusco, D Hayes, FA
Citation: Sm. Lichtman et al., Treatment of aggressive non-Hodgkin's lymphoma in elderly patients with thiotepa, novantrone (mitoxantrone), vincristine, prednisone (TNOP), AM J CL ONC, 24(4), 2001, pp. 360-362
Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
Authors: Rai, KR Peterson, BL Appelbaum, FR Kolitz, J Elias, L Shepherd, L Hines, J Threatte, GA Larson, RA Cheson, BD Schiffer, CA
Citation: Kr. Rai et al., Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia., N ENG J MED, 343(24), 2000, pp. 1750-1757
Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses
Authors: Pinilla-Ibarz, J Cathcart, K Korontsvit, T Soignet, S Bocchia, M Caggiano, J Lai, L Jimenez, J Kolitz, J Scheinberg, DA
Citation: J. Pinilla-ibarz et al., Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses, BLOOD, 95(5), 2000, pp. 1781-1787
Acquired factor VIII inhibitors - Successful treatment with an oral outpatient regimen
Authors: Bayer, RL Lichtman, SM Allen, SL Budman, DR Buchbinder, A Fetten, J Kolitz, J Loscalzo, J
Citation: Rl. Bayer et al., Acquired factor VIII inhibitors - Successful treatment with an oral outpatient regimen, AM J HEMAT, 60(1), 1999, pp. 70-71
Malignant hemangioendothelioma presenting as multifocal intraskeletal lesions during pregnancy - A case report
Authors: Ilasi, JA Smilari, TF Kolitz, J Zanzi, I Hajdu, SI
Citation: Ja. Ilasi et al., Malignant hemangioendothelioma presenting as multifocal intraskeletal lesions during pregnancy - A case report, J REPRO MED, 44(1), 1999, pp. 49-52
Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia
Authors: Damle, RN Wasil, T Fais, F Ghiotto, F Valetto, A Allen, SL Buchbinder, A Budman, D Dittmar, K Kolitz, J Lichtman, SM Schulman, P Vinciguerra, VP Rai, KR Ferrarini, M Chiorazzi, N
Citation: Rn. Damle et al., Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia, BLOOD, 94(6), 1999, pp. 1840-1847
Risultati: 1-8 |